A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2011
05/19/2011	WO2011058025A1 N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
05/19/2011	WO2011057993A1 Indazolone derivatives as glycogen synthase activators
05/19/2011	WO2011057986A1 Homoglutamic acid derivatives
05/19/2011	WO2011057974A1 Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
05/19/2011	WO2011057973A1 Oxazoline derivatives for treatment of cns disorders
05/19/2011	WO2011057960A1 Crystalline cdc7 inhibitor salts
05/19/2011	WO2011057959A1 Indole and indazole derivatives as glycogen synthase activators
05/19/2011	WO2011057956A1 Benzisoxazole analogs as glycogen synthase activators
05/19/2011	WO2011057942A1 Insecticidal methods using pyridine compounds
05/19/2011	WO2011057892A1 2,3-dihydrobenzoxazine and 2,3-dihydrobenzothiazine derivates as hif-inhibitors for the treatment of cancer and inflammatory diseases
05/19/2011	WO2011057784A1 Compounds for pim kinase inhibition and for treating malignancy
05/19/2011	WO2011057780A2 Process for preparing ruthenium(0)-olefin complexes
05/19/2011	WO2011057757A1 New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2h)-one derivatives
05/19/2011	WO2011057714A2 Method for preventing the crystallisation of pharmaceuticals in a polymer film
05/19/2011	WO2011057611A1 Polymeric or oligomeric active ingredients having a biocidal effect, method for the production thereof, and composition comprising a polymeric or oligomeric active ingredient
05/19/2011	WO2011057590A1 New macrocyclic derivatives of glycolurils, and methods of preparing and using the same
05/19/2011	WO2011057580A1 Organic dicarboxylic acids, salts and preparation method thereof
05/19/2011	WO2011057477A1 Tetrapeptide analogs, preparation method and use thereof
05/19/2011	WO2011057471A1 Methods and compositions for treating disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine d2l receptor
05/19/2011	WO2011057437A1 Anti-epidemic growth factor receptor antibody and encoding genes and uses thereof
05/19/2011	WO2011057387A1 Nitric oxide amino acid esters for the treatment of chronic pain
05/19/2011	WO2011057386A1 Composition and prophylactic device for enhancing sexual performance or pleasure
05/19/2011	WO2011057382A1 Spirocyclic piperidine derivatives useful as renin inhibitors
05/19/2011	WO2011057350A1 Antisense molecules and methods for treating pathologies
05/19/2011	WO2011057332A1 Anti-inflammatory compounds
05/19/2011	WO2011057331A1 A method for treating obesity
05/19/2011	WO2011057327A1 Anti-inflammatory extract
05/19/2011	WO2011036561A3 Process
05/19/2011	WO2011036305A3 Pdgfrbeta inhibitors for use in the treatment of t-cell lymphoma
05/19/2011	WO2011034274A3 Pharmaceutical compositions comprising bisphosphonate derivatives and high-dose cholecalciferol
05/19/2011	WO2011029775A8 [1,2,4]triazolo [1,5-c]pyrimidine derivatives as hsp90 modulators
05/19/2011	WO2011024077A3 Exon skipping therapy for functional amelioration of semi functional dystrophin in becker and duchenne muscular dystrophy
05/19/2011	WO2011024056A3 An improved process for the preparation of bosentan
05/19/2011	WO2011024049A3 Method for producing proanthocyanidin polymer compositions for pharmaceutical formulations
05/19/2011	WO2011019793A3 Individualized therapy of single gene disorders with genetically modified adult stem cells
05/19/2011	WO2011019752A3 A1 adenosine receptor agonist polymorphs
05/19/2011	WO2011018582A3 Floating microgranules
05/19/2011	WO2011017564A3 Identification and use of compounds for treating persistent pain
05/19/2011	WO2011011376A3 Methods for the preparation and use of aqueous solutions of magnesium valproate hydrate and l-carnitine
05/19/2011	WO2011011351A3 A stable pharmaceutical omeprazole formulation for oral administration
05/19/2011	WO2011009097A9 Methods for treating schizophrenia
05/19/2011	WO2011009047A3 Il-1ra-polymer conjugates
05/19/2011	WO2011008585A3 Methods and compositions for protecting and treating neuroinjury
05/19/2011	WO2011008052A3 Composition for the prevention or treatment of bone diseases comprising colforsin daropate
05/19/2011	WO2011008001A3 Antihypertensive composition containing a ginsenoside-enriched fraction
05/19/2011	WO2011007961A3 Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes
05/19/2011	WO2011006158A3 Targeting nad biosynthesis in bacterial pathogens
05/19/2011	WO2011006079A3 Ophthalmic formulations of reversed liquid crystalline phase materials and methods of using
05/19/2011	WO2011003065A3 Pyrazolopyrimidine jak inhibitor compounds and methods
05/19/2011	WO2011003018A3 Halogenated 2-deoxy-lactones, 2'-deoxy--nucleosides, and derivatives thereof
05/19/2011	WO2011002852A3 Pro-drug complexes and related methods of use
05/19/2011	WO2010151799A3 Compounds for modulating rna binding proteins and uses therefor
05/19/2011	WO2010151784A3 Antimicrobial compounds
05/19/2011	WO2010151778A3 Topical compositions and methods for wound care
05/19/2011	WO2010151740A4 Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
05/19/2011	WO2010151338A3 Myostatin inhibitor enhancement of musculoskeletal repair
05/19/2011	WO2010151080A3 Pharmaceutical composition containing carboxylosartan and a production method therefor
05/19/2011	WO2010151074A3 Photosensitizer containing conjugates of quantum dot-chlorine derivatives and composition for treating and diagnosing cancer containing same for photodynamic therapy
05/19/2011	WO2010151073A3 Conjugates of anticancer chemotherapeutic agent-chlorine derivatives, photosensitizer containing same and composition for treating cancer containing same
05/19/2011	WO2010151020A3 Fast-dissolving oral film for effectively concealing unpleasant tastes
05/19/2011	WO2010151005A3 Injectable composition containing hydroxychloroquine for local administration for treating cancer
05/19/2011	WO2010151004A3 Injectable composition containing hydroxychloroquine for local administration for treating hemorrhoids
05/19/2011	WO2010149598A3 Heterocyclic antiviral compound
05/19/2011	WO2010148288A3 Pharmaceutical formulations with low aqueous levels of free unbound drug
05/19/2011	WO2010148191A3 Compositions and methods for cyclofructans as separation agents
05/19/2011	WO2010147938A3 Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
05/19/2011	WO2010147387A3 Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides as active ingredients
05/19/2011	WO2010144140A3 Egfr and par2 regulation of intestinal permeability
05/19/2011	WO2010136000A4 Steroide anionic compounds, method of their production, usage and pharmaceutical preparation involving them
05/19/2011	WO2010130799A3 Method for impregnation with supercritical co2
05/19/2011	WO2010111634A3 Renin inhibitors
05/19/2011	WO2010102252A9 Oral dosage forms having a high loading of a gabapentin prodrug
05/19/2011	WO2010074588A3 Pharmaceutical compounds
05/19/2011	WO2010057856A8 Use of escin for treatment of type iv hypersensitivity reaction
05/19/2011	WO2009135179A3 The use of solid carrier particles to improve the processability of a pharmaceutical agent
05/19/2011	WO2008150446A8 Inhibitors of protein kinases
05/19/2011	WO2007121156A8 Rnai-mediated inhibition of histamine receptor h1-related conditions
05/19/2011	WO2007046083A3 Compositions for treatment of eye diseases
05/19/2011	US20110119775 Hydrazide-containing cftr inhibitor compounds and uses thereof
05/19/2011	US20110118825 Anti-angiogenic compositions and methods of use
05/19/2011	US20110118528 Methods and Nutritional Formulations to Increase the Efficacy and Reduce the Side Effects of Cancer Treatment
05/19/2011	US20110118470 Nitrogen-containing aromatic derivatives
05/19/2011	US20110118456 Interfering RNA Molecules
05/19/2011	US20110118445 Inhibitor protein of the wnt signal pathway
05/19/2011	US20110118360 Agent for activating stem cells
05/19/2011	US20110118359 Ampk activating agent
05/19/2011	US20110118358 Deuterium-enriched salmeterol
05/19/2011	US20110118357 Process for preparing o-desmethylvenlafaxine
05/19/2011	US20110118355 Treatment of migraine headaches using antiestrogens
05/19/2011	US20110118354 Cyclohexenyl modulators of chemokine receptor activity
05/19/2011	US20110118353 Method of hormone suppression in humans
05/19/2011	US20110118352 Oat extracts: refining, compositions and methods of use
05/19/2011	US20110118351 Stabilized Formulations of Fatty Acids
05/19/2011	US20110118350 Composition for preventing cardiovascular event in high-risk patient
05/19/2011	US20110118349 Use of prostaglandins f2alpha and analogues for the healing of corneal and conjunctival lesions
05/19/2011	US20110118348 Methods of stabilizing latanoprost in an aqueous solution
05/19/2011	US20110118347 TREATMENT Of RINGWORM
05/19/2011	US20110118346 Novel use of lignan-type compounds or extract of nutmeg or aril of nutmeg comprising the same
05/19/2011	US20110118345 Composition and method for treating diabetes and metabolic disorders
05/19/2011	US20110118344 Novel compound having inhibitory effect on lipase

1 ... 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 ... 7860